Date: 2014-12-16
Type of information: Establishment of a new subsidiary in the EU
Compound: oncology biomarker hsa-miR-31-3p
Company: Integragen (France) investigators from the PICCOLO study
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease: metastatic colorectal cancer
Details: * On December 16, 2014, IntegraGen, a player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced a collaboration with investigators from the PICCOLO study to validate the oncology biomarker hsa-miR-31-3p, a microRNA whose
expression has been shown to be a predictor of progression free survival (PFS) in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.
The PICCOLO study is a randomized clinical trial comparing irinotecan alone to irinotecan in combination with panitumumab, an anti-EGFR antibody, in 460 KRAS wild-type mCRC patients who progressed after receiving fluoropyrimidine treatment with or without oxaliplatin. Initial results from the PICCOLO study were published in Lancet Oncology in July 2013. While the study authors reported no difference in overall survival (OS) between the two study arms, individuals in the panitumumab group had significantly improved progression free survival (PFS) versus the control arm. The present collaboration with IntegraGen will explore the expression levels of hsa-miR-31-3p in primary tumors from patients enrolled in the PICCOLO study and aims to reconfirm the ability of this biomarker to predict patient outcomes.The PICCOLO Study is funded by Cancer Research UK (clinical trial number ISRCTN93248876).
Financial terms:
Latest news:
